Abstract:BackgroundSerum thyroglobulin (Tg) is a key biomarker used to detect disease recurrence in patients with differentiated thyroid cancers who have undergone complete thyroidectomy. Thyroglobulin antibodies (TgAb) can interfere with accurate measurement of serum Tg levels, producing falsely low results in automated immunoassays. Thus before measurement of Tg, TgAb levels are measured to determine if in-house immunoassays can be used or if the patient's sample will need to be sent out for radioimmunoassay (RIA) or mass spectrometry methodologies, which are less sensitive to TgAb interference. We recently transitioned to new instrumentation and noted a sharp increase in Tg samples with TgAb interference that needed to be sent out when we used the limit of detection (LOD) of the Roche TgAb assay. This increases turnaround times for patients and increases laboratory costs. We hypothesized that the LOD of the Roche TgAb assay is below the level of interference in Tg immunoassays. To test this we compared the performance of TgAb immunoassays (IA) and Tg measurements by IA and RIA with the intention of proposing a more appropriate threshold for TgAb interference for the Roche TgAb assay.MethodsWe collected 121 serum specimens, which were above the LOD of the Roche TgAb (R-TgAb) assay, which is 10 IU/mL. These specimens were sent as part of standard care to USC for measurement of TgAb by Kronus (K-TgAb) and Tg by RIA. On these split samples we also measured Tg by Beckman Access (B-Tg). We compared the detection of TgAb by USC to varying thresholds of Roche TgAb measurements (10 IU/mL [LOD], 20 IU/mL, and 115 IU/mL [reference interval for autoimmunity]), and assessed the agreement between Tg measurements by Beckman IA and USC RIA for different Roche TgAb thresholds. Analyses were performed in Prism Graphpad using linear regression.ResultsQualitatively, the concordance for R-TgAb to RIA (reference) at 10 IU/mL was 31%, at 20 IU/mL was 90%, and at 115 IU/mL was 80%. Quantitative agreement between the B-Tg immunoassay and RIA for the TgAb thresholds of: TgAb >10 IU/mL gave an R 2 =0.97 for Tg comparison, >20 IU/mL gave an R 2 =0.99, and >115 IU/mL R 2 =0.99.ConclusionsPrior studies have shown that TgAb immunoassays can produce significant qualitative and quantitative differences. In our study, we attempt to validate the use of the Roche immunoassay with a cutoff of 20 IU/mL to minimize interference between Tg and TgAb in order to accurately detect recurrence of thyroid cancer. We found that a TgAb cutoff of 20 IU/mL we maintained acceptable agreement between Tg methods indicating no significant interference up to 20 IU/mL. With the TgAb cutoff of 20 IU/mL, we would be able to reduce sendouts for this cohort from 121 to 42, reducing sendouts by 65% and allowing a faster turnaround time for a significant proportion of our patients.

A Novel Preanalytical Method for Enhancing Thyroglobulin Measurement in the Presence of Tg Antibodies

Challenges and current advances in the methodology of thyroglobulin measurements

B-085 Optimizing Thyroglobulin Antibody Interference Thresholds to Minimize Turn-around Time

A Novel Thyroglobulin Immunoassay Using the Specimen-Pretreatment Process Improves the Accuracy of Thyroglobulin Measurements in Anti-Thyroglobulin Positive Specimens

Influence of Thyroglobulin (Tg) Autoantibodies on Tg levels Measured by Different Methodologies: (IMA, LC-MS/MS and RIA)

Novel approach to the measurement of antithyroglobulin antibodies in human serum - application of the quartz crystal microbalance sensors

Diagnostic, Theranostic and Prognostic Value of Thyroglobulin in Thyroid Cancer

Serial Stimulated Thyroglobulin Measurements Are More Specific for Detecting Distant Metastatic Differentiated Thyroid Cancer Before Radioiodine Therapy

Establishment of an Indirect ELISA Using Recombinant Human Thyroglobulin for Detecting TgAb and Its Preliminary Application

Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer

Clinical and Laboratory Aspects of Thyroglobulin and Thyroglobulin Antibody in Differentiated Thyroid Carcinoma

AntiThyroglobulin Antibody as a Prognostic Factor to Evaluate the Recurrence and Metastases of Differentiated Thyroid Carcinoma following Radioactive Iodine Ablation

Is Stimulated Thyroglobulin Before Radioiodine Therapy a Useful Tool in Predicting Response to Initial Therapy in Patients with Differentiated Thyroid Carcinoma?

Pre-operative thyroglobulin measurement for thyroid cancer risk of recurrence and response to therapy

Data-Driven Thyroglobulin Cutoffs for Low- and Intermediate-Risk Thyroid Cancer Follow-Up: ITCO Real-World Analysis

Value of Serial Preablative Thyroglobulin Measurements

Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study

Prognostic Value of Serum Thyroglobulin Measured at 48 Hours Versus 72 Hours after Second Dose of Recombinant Human Thyrotropin in Surveillance of Well-Differentiated Thyroid Cancer

Predictive Role of Serum Thyroglobulin after Surgery and before Radioactive Iodine Therapy in Patients with Thyroid Carcinoma

Value of serial preablative thyroglobulin measurements: can we address the impact of thyroid remnants?